These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 17934328

  • 1. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V, Herrling P.
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract] [Full Text] [Related]

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO, Herrling P.
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract] [Full Text] [Related]

  • 3. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO, Herrling P.
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract] [Full Text] [Related]

  • 4. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO, Fischer F, Matthisson M, Herrling P.
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract] [Full Text] [Related]

  • 5. List of drugs in development for neurodegenerative diseases.
    Fischer F, Matthisson M, Herrling P.
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract] [Full Text] [Related]

  • 6. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V, Herrling P.
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract] [Full Text] [Related]

  • 7. Neuroprotection in progressive brain disorders.
    Djaldetti R, Lev N, Melamed E.
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [Abstract] [Full Text] [Related]

  • 8. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ, Youdim MB, Carroll RT, Van der Schyf CJ.
    Prog Neurobiol; 2011 Sep 01; 94(4):347-59. PubMed ID: 21536094
    [Abstract] [Full Text] [Related]

  • 9. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V, Herrling P.
    Neurodegener Dis; 2009 Sep 01; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract] [Full Text] [Related]

  • 10. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L, Kwon MO, Herrling P.
    Neurodegener Dis; 2004 Sep 01; 1(6):269-322. PubMed ID: 16908978
    [No Abstract] [Full Text] [Related]

  • 11. Stimulating the cell's appetite for itself.
    Simonsen A, Stenmark H.
    Nat Chem Biol; 2007 Jun 01; 3(6):304-6. PubMed ID: 17510644
    [No Abstract] [Full Text] [Related]

  • 12. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B.
    IDrugs; 2009 Jun 01; 12(6):349-52. PubMed ID: 19517313
    [No Abstract] [Full Text] [Related]

  • 13. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R, Lestage P, Onteniente B, table ronde no 4 de Giens XXI (2005).
    Therapie; 2007 Jun 01; 62(6):463-72. PubMed ID: 18316011
    [No Abstract] [Full Text] [Related]

  • 14. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V, Herrling P.
    Neurodegener Dis; 2011 Jun 01; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract] [Full Text] [Related]

  • 15. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC, Drory VE.
    J Neurol; 2000 Dec 01; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacotherapy for degenerative dementias].
    Maloteaux JM.
    Bull Mem Acad R Med Belg; 2005 Dec 01; 160(1-2):109-17; discussion 118-22. PubMed ID: 16116815
    [Abstract] [Full Text] [Related]

  • 17. Neuroprotection by tetracyclines.
    Domercq M, Matute C.
    Trends Pharmacol Sci; 2004 Dec 01; 25(12):609-12. PubMed ID: 15530637
    [Abstract] [Full Text] [Related]

  • 18. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions.
    Exp Biol Med (Maywood); 2008 Nov 01; 233(11):vi. PubMed ID: 18957631
    [No Abstract] [Full Text] [Related]

  • 19. [Is good old minocycline a new neuroprotective drug?].
    Melero-Fernández de Mera RM, García-Martínez E, Fernández-Gómez FJ, Hernández-Guijo JM, Aguirre N, Galindo MF, Jordán J.
    Rev Neurol; 2008 Nov 01; 47(1):31-8. PubMed ID: 18592478
    [Abstract] [Full Text] [Related]

  • 20. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
    Geldenhuys WJ, Van der Schyf CJ.
    Expert Opin Drug Discov; 2013 Feb 01; 8(2):115-29. PubMed ID: 23231597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.